Welcome to our dedicated page for Carisma Therapeutics SEC filings (Ticker: CARM), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Decoding Carisma Therapeutics’ biotech disclosures can feel like reading advanced immunology. The company’s CAR-M pipeline, Moderna collaboration, and multi-indication studies load each 10-K and 10-Q with dense data on R&D burn, cGMP manufacturing, and trial risk factors. Even a one-page 8-K may hide a pivotal HER2 update investors cannot ignore.
Stock Titan eliminates that blind spot. Our AI delivers Carisma Therapeutics SEC filings explained simply: every Carisma Therapeutics annual report 10-K simplified, every Carisma Therapeutics quarterly earnings report 10-Q filing annotated, and each Carisma Therapeutics earnings report filing analysis ready the moment EDGAR posts. Need alerts? Carisma Therapeutics Form 4 insider transactions real-time are flagged seconds after submission, so you track Carisma Therapeutics insider trading Form 4 transactions without scanning pages of legalese.
Use our tools to answer real questions faster:
- Monitor Carisma Therapeutics executive stock transactions Form 4 to gauge management confidence.
- Compare pipeline spending across quarters with AI-tagged cash-runway metrics.
- Dive into the proxy statement executive compensation tables without wrestling with footnotes.
- See every Carisma Therapeutics 8-K material events explained in plain English within minutes of filing.
Carisma Therapeutics (NASDAQ:CARM) has issued a Preliminary Proxy Statement for a virtual Special Meeting at an undisclosed 2025 date. Shareholders will vote on two items:
- Proposal 1 – Reverse Stock Split: Authorizes the Board to implement a 1-for-10 to 1-for-50 reverse split at its discretion.
- Proposal 2 – Adjournment: Permits adjournment if additional proxy solicitation time is required.
The reverse split is central to regaining Nasdaq listing compliance. Carisma is currently deficient under three rules: (i) Market Value of Listed Securities ($50 M), (ii) Market Value of Publicly Held Shares ($15 M) and (iii) Minimum Bid Price ($1.00). A Nasdaq Hearings Panel has granted an extension until October 7 2025; the company must post a ≥$1.00 bid for ten consecutive days and otherwise meet Capital Market standards during that period.
Management states the split is also a closing condition for the pending merger with Ocugen’s subsidiary OrthoCellix. Nasdaq rules require the combined entity to trade at ≥$4.00 per share before closing. Failure to approve the split could jeopardize both continued listing and the merger.
Only holders of record on a forthcoming record date may vote via internet, telephone, mail, or live during the virtual meeting. The proxy materials are available at www.investorvote.com/CARM.
FAQ
What is the current stock price of Carisma Therapeutics (CARM)?
What is the market cap of Carisma Therapeutics (CARM)?
What is Carisma Therapeutics Inc.'s primary focus?
How does the CAR-M platform work?
In which therapeutic areas does Carisma operate?
What distinguishes Carisma's approach from other cell therapies?
What role do strategic collaborations play in Carisma’s business model?
How is Carisma addressing challenges in solid tumor treatment?
What recent strategic changes have been implemented by Carisma Therapeutics?
What benefits do engineered macrophages offer in liver fibrosis treatment?
